May 15 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved the expanded use of Bristol Myers Squibb's cancer cell therapy Breyanzi to include the treatment of adults with a type of blood cancer that has returned or has not responded to prior treatments. (Reporting by Sneha S K and Bhanvi Satija in Bengaluru; Editing by Shailesh Kuber)